Antiviral therapy of hepatitis C with 1 genotype after liver transplantation

Vestnik Transplantologii i Iskusstvennyh Organov

O. M. Tsiroulnikova¹  D. V. Umrik² 

[1] V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationI.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University);V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation;

关键词: chronic hepatitis c;    relapse;    liver transplantation;    direct antiviral action;    resistant virologic response.;   

DOI  :  10.15825/1995-1191-2018-3-105-115

来源: DOAJ

【 摘 要 】

Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in  all patients with persistent replication of the virus. Against the background of the  necessary immunosuppressive therapy, the progression of the disease accelerates,  leading to rapid decompensation of the liver. Antiviral therapy significantly improves  the results of transplantation, but the use of standard interferon-based  regimens is associated with low efficacy (no more than 30% for the most common 1  genotype of the virus) and poor tolerance. The article describes new interferon- free oral regimens used to treat the recurrence of HCV infection of 1 genotype.

【 授权许可】

Unknown